Theravance Biopharma Inc. (NASDAQ:TBPH) was down 1.5% during trading on Monday . The stock traded as low as $22.99 and last traded at $23.19, with a volume of 57,800 shares trading hands. The stock had previously closed at $23.55.

Several equities research analysts have recently commented on TBPH shares. Leerink Swann upped their price target on shares of Theravance Biopharma to $29.00 and gave the company an “outperform” rating in a research report on Monday, June 20th. Zacks Investment Research raised shares of Theravance Biopharma from a “hold” rating to a “buy” rating and set a $26.00 price target for the company in a research report on Tuesday, July 12th. Guggenheim started coverage on shares of Theravance Biopharma in a research report on Monday, June 20th. They set a “buy” rating and a $30.00 price target for the company. TheStreet raised shares of Theravance Biopharma from a “sell” rating to a “hold” rating in a research report on Monday, March 21st. Finally, Bank of America Corp. lowered shares of Theravance Biopharma from a “buy” rating to a “neutral” rating in a research report on Thursday, May 5th. Three analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. Theravance Biopharma has an average rating of “Buy” and a consensus price target of $24.75.

The stock’s market capitalization is $1.11 billion. The stock has a 50 day moving average of $23.01 and a 200-day moving average of $19.38.

Theravance Biopharma (NASDAQ:TBPH) last issued its quarterly earnings data on Monday, May 9th. The biopharmaceutical company reported ($1.10) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.96) by $0.14. The company earned $18.40 million during the quarter, compared to the consensus estimate of $18.69 million. On average, equities research analysts predict that Theravance Biopharma Inc. will post ($4.24) earnings per share for the current fiscal year.

A hedge fund recently raised its stake in Theravance Biopharma stock. OppenheimerFunds Inc. raised its stake in Theravance Biopharma Inc. (NASDAQ:TBPH) by 1.1% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,103,485 shares of the biopharmaceutical company’s stock after buying an additional 12,120 shares during the period. OppenheimerFunds Inc. owned 2.92% of Theravance Biopharma worth $18,086,000 at the end of the most recent reporting period.

Theravance Biopharma, Inc is a biopharmaceutical company. The Company is engaged in creating medicines that make a difference in the lives of patients suffering from serious illness. The Company operates in the segment of discovery (research), development and commercialization of human therapeutics. The Company’s pipeline of internally discovered product candidates includes medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.